- Zacks•5 hours ago
Incyte (INCY) announced pooled analysis of five-year data from two phase III studies on Jakafi, which support previous long-term results.
- Business Wire•yesterdayPooled Analysis of Five-Year Data from Two Phase 3 Studies Further Supports Overall Survival Advantage Observed in Patients with Myelofibrosis Treated With Jakafi® (ruxolitinib)
Incyte Corporation today announces an exploratory pooled analysis of data from the five-year follow-up of the Phase 3 COMFORT-I and COMFORT-II trials which further supports previously published overall survival findings and suggests that earlier treatment with Jakafi® may result in an improved survival advantage for patients with intermediate-2 or high-risk myelofibrosis than best available therapy ...
INCY : Summary for Incyte Corporation - Yahoo Finance
Incyte Corporation (INCY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||104.81 x 100|
|Ask||104.89 x 400|
|Day's Range||102.16 - 105.89|
|52 Week Range||55.00 - 118.49|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||140.12|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|